Citations 3

Developing the Novel Sorbent ZO as an Oral Gut Oxalate Binder: Therapeutic Implications for Hyperoxaluria, Hyperoxalemia, and Related Disorders

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025x52k9392

Comparative Effectiveness of Ultrathin vs. Standard Strut Drug-Eluting Stents: Insights from a Large-Scale Meta-Analysis with Extended Follow-up

No container title available | April 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4165985/v1

Abstract Background: Newer generation ultrathin strut stents are associated with less incidence of target lesion failure (TLF) in patients undergoing percutaneous coronary intervention (PCI) in the short term. However, its long-term effect on different cardiovascular outcomes remains unknown. Objectives: We aim to identify the effects of newer-generation ultrathin-strut stents vs. standard thickness second-generation drug eluting stents (DES) on long term outcomes of revascularization in coronary artery disease. Methods: We searched PubMed, Web of Science, Cochrane Library databases, and Scopus for randomized controlled trials (RCTs) and registries that compare newer-generation ultrathin-strut (<70 mm) with thicker-strut (>70 mm) DES to evaluate cardioprotective effects over a period of up to 5 years. Primary outcome was TLF, a composite of cardiac death, target vessel myocardial infarction (TVMI) or target lesion revascularization (TLR). Secondary outcomes included the components of TLF, stent thrombosis (ST), and all-cause death were pooled as the standardized mean difference between the two groups from baseline to endpoint. Results: We included 19 RCTs and two prospective registries (96756 patients) in this analysis. The overall effect on the primary outcome was in favor of second-generation ultrathin struts stents in terms of TLF at ≥ one year, ≥ two years, and ≥ three years (P value= 0.01, 95% CI [0.75, 0.96]), P value=0.003, 95% CI [0.77, 0.95]), P value= 0.007, 95% CI [0.76, 0.96]), respectively. However, there was no reported benefit in terms of TLF when we compared the two groups at ≥ five years (P value= 0.21), 95% CI [0.85, 1.04]). Some of the reported components of the primary and secondary outcomes, such as TLR, target vessel revascularization (TVR), and TVMI, showed the same pattern as the TLF outcome. Conclusion: Ultrathin-strut DES showed a beneficial effect over thicker strut stents for up to three years. However, at the 5-year follow-up, the ultrathin strut did not differ in terms of TLF, TLR, TVR, and TVMI compared with standard-thickness DES, with similar risks of patient-oriented composite endpoint (POCE), MI, ST, cardiac death, and all-cause mortality.
Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

Hepatology | November 4, 2019 | Volume: 71 | Issue: 4 | Pages: 1511-1514

10.1002/hep.31017 | PMID 31680292